AstraZeneca (AZN) Stock Rating Reaffirmed by Jefferies Group

Jefferies Group reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Tuesday morning. They currently have a GBX 5,500 ($74.59) target price on the biopharmaceutical company’s stock.

AZN has been the subject of several other research reports. UBS Group set a GBX 4,550 ($61.70) price target on AstraZeneca and gave the stock a neutral rating in a research note on Monday, January 8th. Morgan Stanley set a GBX 4,700 ($63.74) price target on AstraZeneca and gave the stock a neutral rating in a research note on Friday, October 20th. Deutsche Bank reiterated a buy rating and set a GBX 5,600 ($75.94) price target on shares of AstraZeneca in a research note on Wednesday, October 11th. JPMorgan Chase & Co. set a GBX 4,500 ($61.03) price target on AstraZeneca and gave the stock a neutral rating in a research note on Wednesday, October 18th. Finally, Shore Capital reiterated a hold rating on shares of AstraZeneca in a research note on Monday, October 23rd. Four analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of Hold and an average price target of GBX 5,219 ($70.78).

AstraZeneca (LON:AZN) opened at GBX 5,043 ($68.39) on Tuesday. AstraZeneca has a 52 week low of GBX 4,136.50 ($56.10) and a 52 week high of GBX 5,520 ($74.86). The company has a market capitalization of $63,860.00 and a PE ratio of 2,508.96.

WARNING: “AstraZeneca (AZN) Stock Rating Reaffirmed by Jefferies Group” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was stolen and republished in violation of US & international copyright legislation. The correct version of this article can be viewed at https://www.tickerreport.com/banking-finance/3146901/astrazeneca-azn-stock-rating-reaffirmed-by-jefferies-group.html.

AstraZeneca Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.